MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$2,030,765
EPS
-$0.33
Unit: Dollar

Income Statement
2025-09-30
Research and development costs
50,696
General and administrative costs
1,750,658
Total costs and expenses
1,801,354
Loss from operations
-1,801,354
Interest income
4,430
Interest expense
457
Unrealized gain (loss) on digital assets
-182,887
Realized gain (loss) on foreign currency transactions
-130
Net loss
-1,980,398
Series b convertible preferred stock 8 cumulative dividend
-50,367
Net loss attributable to common stockholders
-2,030,765
Basic EPS
-0.33
Diluted EPS
-0.33
Basic Average Shares
6,171,195
Diluted Average Shares
6,171,195
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to common...-$2,030,765 Net loss-$1,980,398 Series b convertiblepreferred stock 8...-$50,367 Interest income$4,430 Loss from operations-$1,801,354 Unrealized gain (loss) ondigital assets-$182,887 Interest expense$457 Realized gain (loss) onforeign currency...-$130 Total costs andexpenses$1,801,354 General andadministrative costs$1,750,658 Research and developmentcosts$50,696

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)